Catriona Yale - Mar 4, 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Mar 4, 2024
Transactions value $
-$444,602
Form type
4
Date filed
3/6/2024, 08:13 PM
Previous filing
Dec 18, 2023
Next filing
Mar 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $63.6K +10K +12.75% $6.36 88.4K Mar 4, 2024 Direct F1, F2
transaction AKRO Common Stock Options Exercise $225K +10.6K +12.04% $21.09 99.1K Mar 4, 2024 Direct F1
transaction AKRO Common Stock Sale -$733K -20.6K -20.84% $35.49 78.4K Mar 4, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -10K -39.73% $0.00 15.2K Mar 4, 2024 Common Stock 10K $6.36 Direct F1, F3
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -10.6K -12.52% $0.00 74.4K Mar 4, 2024 Common Stock 10.6K $21.09 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 23, 2023, previously adopted by the Reporting Person.
F2 Includes 505 shares acquired under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2023.
F3 The options are vested and currently exercisable.